Cargando…

Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report

Hepatic involvement in familial Mediterranean fever (FMF) ranges from a nonspecific increase in liver enzymes to cryptogenic cirrhosis, and the liver is mostly involved in patients bearing the M694V MEFV mutation in homozygosis. A 44-year-old Jewish woman with FMF developed nonalcoholic steatohepati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massaro, Maria Grazia, Pompili, Maurizio, Sicignano, Luca L., Pizzolante, Fabrizio, Verrecchia, Elena, Vecchio, Fabio M., Rigante, Donato, Manna, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485480/ https://www.ncbi.nlm.nih.gov/pubmed/32952970 http://dx.doi.org/10.4084/MJHID.2020.059

Ejemplares similares

Early introduction of anakinra improves acute pericarditis and prevents tamponade in Staphylococcal sepsis
por: Sicignano, Ludovico Luca, et al.
Publicado: (2021)

Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans
por: Manna, Raffaele, et al.
Publicado: (2019)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Survey about the Quality of Life of Italian Patients with Fabry Disease
por: Polistena, Barbara, et al.
Publicado: (2021)

The Use of Chitotriosidase as a Marker of Active Sarcoidosis and in the Diagnosis of Fever of Unknown Origin (FUO)
por: Di Francesco, Angela Maria, et al.
Publicado: (2021)

Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome
por: Cantarini, Luca, et al.
Publicado: (2017)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases
por: Tsinti, Maria, et al.
Publicado: (2014)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever
por: Verrecchia, E., et al.
Publicado: (2017)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients
por: Laskari, K, et al.
Publicado: (2015)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
por: Karabulut, Yusuf, et al.
Publicado: (2022)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
por: Kacar, Mark, et al.
Publicado: (2020)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
por: Kavrul Kayaalp, Gülşah, et al.
Publicado: (2023)

Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review
por: Talerico, Rosa, et al.
Publicado: (2020)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020)

The everchanging framework of autoinflammation
por: Manna, Raffaele, et al.
Publicado: (2021)

Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever
por: Marinelli, Francesca, et al.
Publicado: (2022)

From the Mediterranean to the Sea of Japan: The Transcontinental Odyssey of Autoinflammatory Diseases
por: Rigante, Donato, et al.
Publicado: (2013)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Evidence of evolution towards left midventricular obstruction in severe Anderson–Fabry cardiomyopathy
por: Graziani, Francesca, et al.
Publicado: (2020)

Mediterranean spotted fever with multiorgan involvement
por: Davis, Kimberly, et al.
Publicado: (2022)

Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease
por: Graziani, Francesca, et al.
Publicado: (2020)

Blockage of interleukin-1β with canakinumab in patients with Covid-19
por: Landi, Lorenza, et al.
Publicado: (2020)

Articular involvement in childhood Familial Mediterranean Fever
por: Barut, K, et al.
Publicado: (2015)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Case report on the use of canakinumab for treatment of recurrent fevers and proteinuria in refractory systemic lupus erythematosus
por: Yavari, Kimia, et al.
Publicado: (2023)

PW01-024 – Phenotypic analysis of a MEFV negative FMF cohort
por: Soriano, A, et al.
Publicado: (2013)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Off-label use of canakinumab in pediatric rheumatology and rare diseases
por: Del Giudice, Emanuela, et al.
Publicado: (2022)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sh6cpn08jns9qk7iae7hpg02ml